LMLucas Monteiro Molina

Lucas Monteiro Molina

*This is an algorithmically generated author record based on publicly available information.


Latest Publications

  • Open Access

    Recent Advances in Understanding and Managing Alzheimer's Disease: from Pathogenesis to Treatment

    by Rafael Leituga de Carvalho Cavalcante, Maurício Samartino, Larissa Abussafi Miranda, Jeniffer da Silva Alencar Mendes, Tatiana de Lima Tanaka, Felipe de Oliveira Silva, Lucas Monteiro Molina, Bruno Carvalho Diniz, Daniela Alves Dantas, Dhyana Ataide Ferraz Sarges, et al.

    Objective: The objective of this article is to conduct a comprehensive review of recent advances in understanding the pathogenesis of Alzheimer's disease (AD) and innovations in its management, emphasizing how these developments can inform more effective therapeutic strategies. Initially, this study explores contemporary findings related to the molecular and cellular mechanisms contributing to AD pathology, including the aggregation of beta-amyloid and tau, neural inflammation, synaptic dysfunction, as well as the impact of genetic and environmental factors. Theoretical Framework: Alzheimer's disease (AD) presents itself as a growing challenge for global public health, given its rising prevalence and the significant impact on the affected individuals, their families, and the healthcare systems. Method: A systematic review was conducted using major scientific databases to collect relevant articles on recent advances in the understanding and management of Alzheimer's disease, from pathogenesis to treatment. Specific keywords were used to identify studies addressing new findings and interdisciplinary therapeutic strategies. This enabled the synthesis of effective approaches and the identification of research gaps, supporting evidence-based clinical practices. Results and Discussion: Recent research has identified novel genetic markers linked to Alzheimer's disease, enhancing early diagnosis. Studies have also demonstrated the efficacy of integrated cognitive therapies in slowing disease progression. Additionally, new pharmacological treatments targeting amyloid plaques have shown promise in clinical trials. However, challenges in uniform treatment efficacy across diverse populations highlight the need for tailored therapeutic approaches.